Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer
AuthorRichardsen, Elin; Andersen, Sigve; Al-Saad, Samer; Rakaee, Mehrdad; Nordby, Yngve; Pedersen, Mona Irene; Ness, Nora; Ingebriktsen, Lise; Fassina, Ambrogio; Tasken, Kristin Austlid; Millls, Ian; Dønnem, Tom; Bremnes, Roy M.; Rasmussen Busund, Lill-Tove
Prostate cancer (PC) is a highly heterogenous disease and one of the leading causes of mortality in developed countries. Recently, studies have shown that expression of immune checkpoint proteins are directly or indirectly repressed by microRNAs (miRs) in many types of cancers. The great advantages of using miRs based therapy is the capacity of these short transcripts to target multiple molecules for the same- or different pathways with synergistic immune inhibition effects. miR-424 has previously been described as a biomarker of poor prognosis in different types of cancers. miR-424 is also found to target both the CTLA-4/CD80- and PD-1/PD-L1 axis. In the present study, the clinical significance of miR-424-3p expression in PC tissue was evaluated. Naïve radical prostatectomy specimens from 535 patients was used for tissue microarray construction. In situ hybridization was used to evaluate the expression of miR-424-3p and immunohistochemistry was used for CTLA-4 protein detection. In univariate- and multivariate analyses, low expression of miR-424-3p was significant associated with clinical failure-free survival, (p = 0.004) and p = 0.018 (HR:0.44, CI95% 0.22–0.87). Low expression of miR-424-3p also associated strongly with aggressive phenotype of PC. This highlight the importance of miR-424-3p as potential target for therapeutic treatment in prostate cancer.
Source at https://doi.org/10.1038/s41598-019-47234-0.